Researcher

Shumin Li

Jilin University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · JOURNAL ARTICLE

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with iruplinalkib resistance

Frontiers in Pharmacology

Single-case report of a treatment strategy in a rare ALK variant; describes clinical response but lacks control group, quantified endpoints, or generalizable evidence.

PreliminaryLung Cancer Research Studies Linfeng Cao Tao Feng

Reported

Time to progression on iruplinalk…6.3 months

Iruplinalkib dose180 mg once daily

Lorlatinib dose100 mg once daily

AUG 12, 2026 · REVIEW

Tyrosine kinase inhibitors and molecularly driven therapeutic approaches for canine lymphoma: a systematic review and meta-analysis

Frontiers in Veterinary Science

Meta-analysis of 11 clinical trials in 101 dogs shows moderate objective response rate (42%) with potential cell-type variation, supporting TKI investigation but requiring confirmation of efficacy, safety, and optimal dosing strategies.

PromisingYali Chen Shumin Li Lymphoma Diagnosis and Treatment

Reported

Objective response rate (ORR)42%

95% CI for ORR32–53%

Sample size (dogs in clinical tri…101